Abstract Details

Title Correlations of CSF Biomarkers of Alzheimer’s Disease with Cognitive Measures in MCI and AD Dementia

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P10 - Poster Session 10 (5:00 PM-6:00 PM)

Poster/Presentation
Number 3-020

Objective Examine the relationship between cerebrospinal fluid (CSF) Aβ1?42, t-tau, p-tau-181, and cognition in the Alzheimer’s Disease Neuroimaging Initiative (ADNI 1, 2, and GO) dataset.

Background Previous studies have examined longitudinal relationships between CSF biomarkers for AD and cognition. However, discordance exists in the strength of associations between CSF biomarkers and cognition at different disease stages. We examined this relationship in a large, cross-sectional ADNI dataset across many cognitive assessments of learning, memory, executive function, language, attention, visuospatial skills, and activities of daily living.

Design/Methods 976 subjects (265 cognitively normal (CN); 518 mild cognitive impairment (MCI); and 193 AD) were included. Cognitive assessments, diagnoses, and specimen collection/processing were conducted per published ADNI protocols. Pearson correlations were performed between CSF biomarkers (Aβ1?42, t-tau, p-tau-181) and the various cognitive measures.

Results

In the MCI cohort, significant (p<0.05) negative correlations were observed between CSF Aβ1?42 and ADAS-Cog11 (r=-0.33), ADAS-Cog13 (r=-0.374), CDR-SB (r=-0.181), Trails B (r=-0.23), and FAQ (r=-0.193). Positive correlations were between Aβ1?42 and RAVLT immediate (r=0.333), MMSE (r=0.254), and Weschler Memory Scale (WMS) Delayed Recall (r=0.294).

Furthermore, significant correlations were observed between CSF t-tau, p-tau and the following cognitive assessments: CDR-SB (r=0.161 and 0.157, respectively), ADAS-Cog11 (r=0.212 and 0.218), ADAS-Cog13 (r=0.275 and 0.279), RAVLT forgetting (r=0.206 and 0.2), Trails B (r=0.117 each), MMSE (r=-0.217 and -0.224), RAVLT immediate (r=-0.235 and -0.242), and WMS Delayed Recall (r=-0.321; -0.324).

In the AD cohort, only Aβ1?42 and MMSE (r=0.143) were correlated. No significant correlations were found between t-tau/p-tau and any cognitive scores.

Conclusions Our findings suggest that the relationship between CSF biomarkers and cognitive performance is most pronounced in MCI individuals. The lack of significant correlations in the AD cohort may indicate other pathophysiological changes dominating cognitive dysfunction at this disease stage. Further research is warranted to explore these biomarkers' longitudinal impacts and predictive value across different stages of disease.

Authors/Disclosures
Gabriel A. Bitar PRESENTER	Mr. Bitar has nothing to disclose.
Sierra L. Alban	Ms. Alban has nothing to disclose.
Kassu Mehari Beyene, PhD	Dr. Beyene has nothing to disclose.
Boris Decourt, PhD	Dr. Decourt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Light House Pharmaceuticals. The institution of Dr. Decourt has received research support from National Institute on Aging. Dr. Decourt has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with National Institute on Aging.
Marwan N. Sabbagh, MD, FAAN (Barrow Neurological Institute)	Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.

��ɫ��

��ɫ��